Jyseleca tablet safety study in Korean patients
Part of Bones, joints & muscles, Digestive system, Immune system & allergy, Skin clinical trials.
This study tracks Korean patients already taking Jyseleca for rheumatoid arthritis or ulcerative colitis, making sure it's safe and working as expected. It's not testing a new drug, just watching how patients do over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking Jyseleca (filgotinib) for rheumatoid arthritis or ulcerative colitis as prescribed by your doctor.
- You are 18 years or older.
- You do not have an active infection, tuberculosis, or severe liver or kidney problems.
- You are not pregnant, breastfeeding, or planning to become pregnant.
- You have not had an allergic reaction to Jyseleca or its ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called JNJ-78934804 to treat ulcerative colitis (inflammation of the colon and rectum) that is moderate to severe and hasn't responded well to standard treatments. The goal is to see if this drug can reduce inflammation and improve symptoms.
This study tracks how well guselkumab (Tremfya) works in real-life for people with inflammatory bowel disease in Germany. If you are starting this treatment, researchers will watch your progress and ask you to fill out simple surveys about your symptoms.
This trial tests new medicines for people with moderate to severe ulcerative colitis who haven't found relief with standard treatments. Participants will receive one of several investigational drugs (these are not yet approved and are being studied for safety and tolerability). The goal is to see if the drugs are safe and if they might help control symptoms.
This study tracks how well guselkumab (Tremfya) works in real-world Chinese patients with moderate to severe ulcerative colitis who haven't tried advanced therapies before. It helps doctors understand how the drug performs outside of controlled trials.
This study collects real-world safety information about Xeljanz XR after it has been approved. It includes people with certain immune-related joint diseases and checks for side effects in everyday use.
This study tracks how well Cosentyx works in real-world use for people with hidradenitis suppurativa, plaque psoriasis, or juvenile idiopathic arthritis. It helps doctors understand the medicine's long-term effects in Korean patients.
Hear when a new Arthritis, Rheumatoid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.